文献速递胰腺与胆道疾病消化内镜消化道肿瘤与早癌

胆管内射频消融根除内镜下乳头切除术后残留肿瘤的有效性与安全性:一项多中心前瞻性研究

Efficacy and safety of endobiliary radiofrequency ablation for the eradication of residual neoplasia after endoscopic papillectomy: a multicenter prospective study.
PubMed 文献 · Gastrointest Endosc · 2018-04-13

这项前瞻性开放标签多中心研究纳入20例内镜下乳头切除术后病理证实的胆管内腺瘤残留(胆管范围<20 mm)患者,行单次胆管内射频消融(ID-RFA,效果8,功率10 W,30秒)并放置胆道支架。6个月和12个月残留肿瘤率分别为15%和30%,仅2例(10%)转手术,8例(40%)发生至少1次不良事件,无重大不良事件;结论认为ID-RFA可作为手术替代方案,单次治疗后12个月不典型增生根除率约70%,但仍需随访。

要点

  • 内镜下乳头切除术后胆管内腺瘤残留(范围<20 mm)可行ID-RFA,单次治疗后12个月不典型增生根除率约70%。
  • 6个月和12个月残留肿瘤率分别为15%和30%,仅2例(10%)转手术治疗。
  • 8例(40%)发生至少1次不良事件,无重大不良事件;纳入时高级别不典型增生与12个月不典型增生复发相关(P = .01)。

核心结论

  • 内镜下乳头切除术后残留胆管内不典型增生行ID-RFA可作为手术的替代选择,单次治疗后12个月不典型增生根除率约70%,安全性良好,但ID-RFA后仍需患者随访。

研究设计与样本

  • 前瞻性开放标签多中心研究,纳入内镜下乳头切除术后病理证实的胆管内腺瘤残留(胆管范围<20 mm)患者20例(年龄67 ± 11岁,男性12例)。
  • RFA参数为效果8、功率10 W、30秒,于ERCP术中完成,术毕放置胆道支架,部分加放胰管支架(5例,25%)。

主要发现

  • 纳入时胆管内腺瘤为低级别不典型增生15例、高级别不典型增生5例。
  • 所有患者均完成1次成功ID-RFA并放置胆道支架,恢复顺利。
  • 6个月和12个月残留肿瘤率分别为15%和30%。
  • 仅2例(10%)转手术治疗。
  • 8例(40%)在ID-RFA至12个月随访期间发生至少1次不良事件,无重大不良事件。

关键数值与推荐

  • ID-RFA参数:效果8、功率10 W、时间30秒。
  • 6个月残留肿瘤率为15%,12个月残留肿瘤率为30%。
  • 转手术率为10%(2例)。
  • 至少1次不良事件发生率为40%(8例),无重大不良事件。
  • 纳入时高级别不典型增生与12个月不典型增生复发相关(P = .01)。

临床怎么用

  • 作者认为,内镜下乳头切除术后残留胆管内不典型增生行ID-RFA可作为手术的替代选择。
  • 作者指出,ID-RFA后仍需患者随访。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Endobiliary dysplasia may persist after endoscopic papillectomy. Intraductal radiofrequency ablation (ID-RFA) is a potential alternative to complementary surgery. The aim of this study was to evaluate the efficacy and safety of ID-RFA for the treatment of adenomatous intraductal residue after endoscopic papillectomy. METHODS: A prospective open-label multicenter study included patients with histologically proven endobiliary adenoma remnant (ductal extent <20 mm) after endoscopic papillectomy for ampullary tumor. RFA (effect 8, power 10 W, 30 seconds) was performed during ERCP. Biliary ± pancreatic stent was placed at the end of the procedure. Endpoints were (1) the rate of residual neoplasia (ie, low-grade dysplasia [LGD], high-grade dysplasia [HGD], or invasive carcinoma) at 6 and 12 months, (2) rate of surgery, and (3) adverse events. RESULTS: Twenty patients (67 ± 11 years of age, 12 men) were included. The endobiliary adenoma was in LGD in 15 patients and HGD in 5 patients. All underwent 1 successful ID-RFA session with biliary stent placement and recovered uneventfully. Five (25%) received a pancreatic stent. The rates of residual neoplasia were 15% and 30% at 6 and 12 months, respectively. Only 2 patients (10%) were referred for surgery. Eight patients (40%) experienced at least 1 adverse event between ID-RFA and 12 months of follow-up. No major adverse event occurred. HGD at inclusion was associated with higher dysplasia recurrence at 12 months (P = .01). CONCLUSIONS: ID-RFA of residual endobiliary dysplasia after endoscopic papillectomy can be offered as an alternative to surgery, with a 70% chance of dysplasia eradication at 12 months after a single session and a good safety profile. Patient follow-up remains warranted after ID-RFA. (Clinical trial registration number: NCT02825524.).

来源:Gastrointest Endosc,查看原文。版权归原作者所有。

引用

  1. Camus M, Napoléon B, Vienne A, et al. Efficacy and safety of endobiliary radiofrequency ablation for the eradication of residual neoplasia after endoscopic papillectomy: a multicenter prospective study. Gastrointest Endosc. 2018. PMID: 29660322. doi:10.1016/j.gie.2018.04.2332

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。